In this report, we explore retinoblastoma diagnostic accuracy and review chemotherapy alternatives for retinoblastoma using intravenous, intra-arterial, periocular, and intravitreal routes. A review of 2775 patients referred for management of retinoblastoma, disclosed 78% with confirmed retinoblastoma and 22% with simulating lesions, termed pseudoretinoblastomas. Children r2 years old showed leading pseudoretinoblastomas of persistent fetal vasculature, Coats disease, and vitreous haemorrhage, whereas those 45 years showed simulators of Coats, toxocariasis, and familial exudative vitreoretinopathy. The diagnosis of retinoblastoma should be established before planning therapeutic strategy. Chemotherapy strategy depends on tumour laterality and stage of disease. If bilateral retinoblastoma, intravenous chemotherapy (IVC) is important as first-line therapy for control of intraocular disease, prevention of metastasis, and reduction in prevalence of pinealoblastoma and long-term second malignant neoplasms. Bilateral groups D and E retinoblastoma receive additional subtenon's carboplatin boost for improved local control. If unilateral disease is present, then intra-arterial chemotherapy (IAC) is often considered. IAC can be salvage therapy following chemoreduction failure. Unilateral retinoblastoma of groups D and E are managed with enucleation or globeconserving IVC and/or IAC. Intravitreal chemotherapy is cautiously reserved for recurrent vitreous seeds following other therapies. In conclusion, the strategy for retinoblastoma management with chemotherapy depends on tumour laterality and stage of disease. Bilateral retinoblastoma is most often managed with IVC and unilateral retinoblastoma with IAC, but if advanced stage, combination IVC plus IAC or enucleation.
Enhanced depth imaging optical coherence tomography reveals characteristic surface topography of choroidal osteoma as dome or undulating (87%) with unique intrinsic features of horizontal lamellar lines (100%), horizontal (60%) or vertical (13%) tubules, and speckled regions (40%). Photoreceptor loss was evident in every case of tumor deossification.
Purpose:To compare the effects of preoperative use of topical anti-inflammatory prednisolone acetate, ketorolac tromethamine, nepafenac and placebo, on the maintenance of intraoperative mydriasis during cataract surgery.Design:Randomized clinical trial.Materials and Methods:This single-center, masked, randomized clinical study comprised 140 patients scheduled for cataract surgery. Patients (35 in each group) were randomized to receive placebo, prednisolone acetate, ketorolac tromethamine 0.4% or nepafenac. These eye drops were administered three times daily for the two days prior to surgery. The pupillary diameters were measured by the surgeon using a compass prior to the corneal section and at the end of surgery. The primary outcome was the number of patients with pupil ≥ 6mm at the end of the surgery; the secondary outcome was the number of patients with pupil ≥ 6mm at the beginning of the surgery.Results:All the patients achieved pupil ≥ 6mm at the beginning of the surgery. The number of patients in the prednisolone (29/35), nepafenac (31/35) and ketorolac (30/35) groups with pupil ≥ 6mm was greater than in the placebo group in the maintenance of intraoperative mydriasis (19/35 – P =0.003). There was no statistical difference among the prednisolone, nepafenac and ketorolac groups in the maintenance of intraoperative mydriasis (P =.791). There were no complications during surgery or related to the preoperative use of the eye drops.Conclusion:Preoperative use of ketorolac, prednisolone and nepafenac was effective in maintaining intraoperative mydriasis when compared with placebo.
Objective: To investigate if E-learning material improves the basal student knowledge level before attending the presential class of blindness prevention (BP) and if helps to fix this information one-month
RESUMOObjetivo: Avaliar se um material disponibilizado através de E-learning antes de aulas presenciais de prevenção da cegueira (PC) melhora o nível de conhecimento basal dos estudantes, e ajuda a manter esse conteúdo um mês após a aula. Métodos: Estudantes do quarto ano do curso médico foram aleatoriamente sorteados para ter aulas presenciais de PC (grupo tradicional = GT) ou ter aulas presenciais precedidas de material adicional por E-learning (grupo E-learning = GEL). Este material foi enviado por correio eletrônico uma semana antes da aula presencial. Os estudantes foram submetidos a testes de múltipla escolha com sete questões (com três alternativas cada) imediatamente antes da aula presencial, imediatamente após a aula, e um mês após a aula. Os três testes tiveram as mesmas questões: entretanto, as respostas foram distribuídas em sequências diferentes. O desfecho primário foi a nota do pré-teste. Os desfechos secundários foram as notas dos pós-teste imediato e do pós-teste tardio. Resultados: Entre os 120 alunos do quarto ano de medicina, uma amostra aleatória de 34 alunos foi selecionada para o grupo GT e 34 alunos para o grupo GEL. Os dois grupos obtiveram nota similar no pós-teste imediato (GT=6.8 e GEL=6.9; P<.754), porém diferenças estatisticamente significativas no pré-teste (GT=3.6 e GEL=4.7; P<.001), e no pós-teste tardio (GT=6.1 e GEL=6.8; P<.001). Conclusão: Os resultados do pré-teste e do pós-teste tardio sugerem que o E-learning pode ser um complemento eficiente do ensino presencial de prevenção da cegueira.
Cutaneous melanoma metastatic to the orbit tends to involve muscle (35%) or intraconal soft tissue (24%) as a painless (75%), circumscribed (87%) mass. Treatment with systemic chemotherapy and/or immunotherapy resulted in orbital tumor control in 80% of cases. Overall survival was 25.1 months.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.